168 related articles for article (PubMed ID: 22985614)
1. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Alioğlu B; Kılıç N; Şimşek E; Dallar Y
J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
[TBL] [Abstract][Full Text] [Related]
2. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
4. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
5. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
Akinci B; Comlekci A; Ali Ozcan M; Demir T; Yener S; Demirkan F; Yuksel F; Yesil S
Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
[TBL] [Abstract][Full Text] [Related]
6. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
7. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
[TBL] [Abstract][Full Text] [Related]
8. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
10. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
Watanabe R; Wada H; Watanabe Y; Sakakura M; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Nobori T; Shiku H
Thromb Res; 2001 Oct; 104(1):1-6. PubMed ID: 11583733
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
Zorio E; Castelló R; Falcó C; España F; Osa A; Almenar L; Aznar J; Estellés A
Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
Bladbjerg EM; Madsen JS; Kristensen SR; Abrahamsen B; Brixen K; Mosekilde L; Jespersen J
J Thromb Haemost; 2003 Jun; 1(6):1208-14. PubMed ID: 12871321
[TBL] [Abstract][Full Text] [Related]
13. Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Akinci B; Demir T; Comlekci A; Yener S; Ozcan MA; Karaoglu O; Yuksel F; Secil M; Yesil S
Med Princ Pract; 2011; 20(1):23-8. PubMed ID: 21160209
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
Binette TM; Taylor FB; Peer G; Bajzar L
Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
[TBL] [Abstract][Full Text] [Related]
16. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
Yüzbaşıoğlu B; Ustaoğlu M; Yüzbaşıoğlu Ş; Akbulut UE; Özdil K
Turk J Gastroenterol; 2019 Dec; 30(12):1025-1029. PubMed ID: 31854307
[TBL] [Abstract][Full Text] [Related]
17. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.
Rigla M; Wägner AM; Borrell M; Mateo J; Foncuberta J; de Leiva A; Ordóñez-Llanos J; Pérez A
Metabolism; 2006 Nov; 55(11):1437-42. PubMed ID: 17046544
[TBL] [Abstract][Full Text] [Related]
18. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
Cetinkalp S; Tobu M; Karadeniz M; Buyukkeçeci F; Yilmaz C
Intern Med; 2009; 48(5):281-5. PubMed ID: 19252348
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
[TBL] [Abstract][Full Text] [Related]
20. Thrombin Activable Fibrinolysis Inhibitor in Beta Thalassemia.
Chhikara A; Sharma S; Chandra J; Nangia A
Indian J Pediatr; 2017 Jan; 84(1):25-30. PubMed ID: 27487812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
